Mereo BioPharma Group PLC (MREO)
4.14
+0.04
(+0.98%)
USD |
NASDAQ |
Sep 27, 16:00
4.14
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Research and Development Expense (Annual): 17.42M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.42M |
| December 31, 2022 | 29.46M |
| December 31, 2021 | 31.80M |
| Date | Value |
|---|---|
| December 31, 2020 | 22.28M |
| December 31, 2019 | 30.95M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.42M
Minimum
2023
31.80M
Maximum
2021
26.38M
Average
29.46M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Adaptimmune Therapeutics PLC | 126.51M |
| NuCana PLC | 31.19M |
| TC BioPharm (Holdings) PLC | 9.670M |
| Biodexa Pharmaceuticals PLC | -- |
| Autolus Therapeutics PLC | 130.48M |